Scinai Immunotherapeutics (SCNI) Total Non-Current Liabilities (2017 - 2025)

Scinai Immunotherapeutics has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $15.6 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $15.6 million, up 837.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.6 million (up 837.96% YoY), and the FY2025 annual result was $15.6 million, up 837.96% from the prior year.
• Total Non-Current Liabilities came in at $15.6 million for Q4 2025 at Scinai Immunotherapeutics, up from $1.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $28.6 million in Q4 2021 to a low of $866000.0 in Q3 2024.
• The 5-year median for Total Non-Current Liabilities is $19.7 million (2023), against an average of $16.1 million.
• Across the five-year window, Total Non-Current Liabilities surged 1157.03% in 2021 and slumped 95.61% in 2024, its largest moves.
• Scinai Immunotherapeutics' Total Non-Current Liabilities stood at $28.6 million in 2021, then declined by 7.41% to $26.5 million in 2022, then decreased by 23.51% to $20.3 million in 2023, then slumped by 91.78% to $1.7 million in 2024, then surged by 837.96% to $15.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $15.6 million (Q4 2025), $1.9 million (Q2 2025), and $1.7 million (Q4 2024), per Business Quant data.